Curative Properties of Noninternalizing Antibody–Drug Conjugates Based on Maytansinoids
Published version of a preprint
Abstract
It is generally thought that the anticancer efficacy of antibody–drug conjugates (ADC) relies on their internalization by cancer cells. However, recent work on an ADC that targets fibronectin in the tumor microenvironment suggests this may not be necessary. The alternatively spliced extra domains A and B (EDA and EDB) of fibronectin offer appealing targets for ADC development, because the antigen is strongly expressed in many solid human tumors and nearly undetectable in normal tissues except for the female reproductive system. In this study, we describe the properties of a set of ADCs based on an antibody targeting the alternatively spliced EDA of fibronectin coupled to one of a set of potent cytotoxic drugs (DM1 or one of two duocarmycin derivatives). The DM1 conjugate SIP(F8)-SS-DM1 mediated potent antitumor activity in mice bearing DM1-sensitive F9 tumors but not DM1-insensitive CT26 tumors. Quantitative biodistribution studies and microscopic analyses confirmed a preferential accumulation of SIP(F8)-SS-DM1 in the subendothelial extracellular matrix of tumors, similar to the pattern observed for unmodified antibody. Notably, we found that treatments were well tolerated at efficacious doses that were fully curative and compatible with pharmaceutical development. Our findings offer a preclinical proof-of-concept for curative ADC targeting the tumor microenvironment that do not rely upon antigen internalization. Cancer Res; 74(9); 2569–78. ©2014 AACR.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ADCs bind to cell surface receptors that are upregulated by mutant RAS.
“They bind to cell surface receptors that are upregulated by mutant RAS and exhibit potent antitumor activity, demonstrating their efficacy in targeting undruggable proteins outside the cell.645–649”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [648]
ADCs exhibit potent antitumor activity.
“They bind to cell surface receptors that are upregulated by mutant RAS and exhibit potent antitumor activity, demonstrating their efficacy in targeting undruggable proteins outside the cell.645–649”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [648]
ADCs demonstrate efficacy in targeting undruggable proteins outside the cell.
“They bind to cell surface receptors that are upregulated by mutant RAS and exhibit potent antitumor activity, demonstrating their efficacy in targeting undruggable proteins outside the cell.645–649”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [648]
Cites
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · see citing works
Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
Chari, R. V. J. (2007) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 819 · see citing works
Senter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 767 · see citing works
Neri, D., & Bicknell, R. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1627 · Cited by 601 · see citing works
Self-citationJunttila, T. T., Li, G., Parsons, K. L., Phillips, G. D. L., & Sliwkowski, M. X. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1090-x · Cited by 539 · see citing works
Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blättler, W. A., & Goldmacher, V. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3973 · Cited by 479 · see citing works
Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature
Huang, X., Molema, G., King, S., Watkins, L. R., Edgington, T. S., & Thorpe, P. E. (1997) · Science · doi:10.1126/science.275.5299.547 · Cited by 477 · see citing works
Design and Use of a Phage Display Library
Pini, A., Viti, F., Santucci, A., Carnemolla, B., Zardi, L., Neri, P., & Neri, D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.34.21769 · Cited by 423 · see citing works
Self-citationPotent antibody drug conjugates for cancer therapy
Senter, P. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.023 · Cited by 403 · see citing works
Borsi, L., Balza, E., Bestagno, M., Castellani, P., Carnemolla, B., Biro, A., Leprini, A., Sepúlveda, J., Burrone, Ó. R., Neri, D., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10662 · Cited by 354 · see citing works
Self-citationImmunoconjugates containing novel maytansinoids: promising anticancer drugs.
CHARI, R. V. J., Martell, B., Gross, J. L., Cook, S., Shah, S. A., Blättler, W. A., McKenzie, S. J., & Goldmacher, V. S. (1992) · PubMed · Cited by 266 · see citing works
Lopus, M., Oroudjev, E., Wilson, L., Wilhelm, S. D., Widdison, W. C., Chari, R. V. J., & Jordan, M. A. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0644 · Cited by 234 · see citing works
Villa, A., Trachsel, E., Kaspar, M., Schliemann, C., Sommavilla, R., Rybak, J., Roesli, C., Borsi, L., & Neri, D. (2008) · International Journal of Cancer · doi:10.1002/ijc.23408 · Cited by 228 · see citing works
Self-citationThe Extra-domain A of Fibronectin Is a Vascular Marker of Solid Tumors and Metastases
Rybak, J., Roesli, C., Kaspar, M., Villa, A., & Neri, D. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1436 · Cited by 212 · see citing works
Self-citationNilsson, F., Kosmehl, H., Zardi, L., & Neri, D. (2001) · PubMed · Cited by 211 · see citing works
Self-citationViti, F., Tarli, L., Giovannoni, L., Zardi, L., & Neri, D. (1999) · PubMed · Cited by 206 · see citing works
Self-citationJohannsen, M., Spitaleri, G., Curigliano, G., Roigas, J., Weikert, S., Kempkensteffen, C., Roemer, A. P., Kloeters, C., Rogalla, P., Pecher, G., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.07.033 · Cited by 183 · see citing works
Self-citationSauer, S., Erba, P. A., Petrini, M., Menrad, A., Giovannoni, L., Grana, C., Hirsch, B., Zardi, L., Paganelli, G., Mariani, G., et al. (2009) · Blood · doi:10.1182/blood-2008-06-160416 · Cited by 173 · see citing works
Self-citationSchwager, K., Kaspar, M., Bootz, F., Marcolongo, R., Paresce, E., Neri, D., & Trachsel, E. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2814 · Cited by 167 · see citing works
Self-citationIssell, B. F., & Crooke, S. T. (1978) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(78)80014-0 · Cited by 151 · see citing works
Schliemann, C., Palumbo, A., Zuberbühler, K., Villa, A., Kaspar, M., Trachsel, E., Klapper, W., Menssen, H. D., & Neri, D. (2008) · Blood · doi:10.1182/blood-2008-05-160747 · Cited by 150 · see citing works
Self-citationMolecular basis for sequence-specific DNA alkylation by CC-1065
Hurley, L. H., Lee, C. S., McGovren, J. P., Warpehoski, M. A., Mitchell, M. A., Kelly, R. C., & Aristoff, P. A. (1988) · Biochemistry · doi:10.1021/bi00410a054 · Cited by 144 · see citing works
Eigentler, T., Weide, B., de Braud, F., Spitaleri, G., Romanini, A., Pflugfelder, A., González‐Iglesias, R., Tasciotti, A., Giovannoni, L., Schwager, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1203 · Cited by 143 · see citing works
Self-citationNiesner, U., Halin, C., Lozzi, L., Günthert, M., Neri, P., Wunderli‐Allenspach, H., Zardi, L., & Neri, D. (2002) · Bioconjugate Chemistry · doi:10.1021/bc025517+ · Cited by 137 · see citing works
Self-citationA Traceless Vascular‐Targeting Antibody–Drug Conjugate for Cancer Therapy
Bernardes, G. J. L., Casi, G., Trüssel, S., Hartmann, I., Schwager, K., Scheuermann, J., & Neri, D. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201106527 · Cited by 133 · see citing works
Self-citationCasi, G., Huguenin‐Dezot, N., Zuberbühler, K., Scheuermann, J., & Neri, D. (2012) · Journal of the American Chemical Society · doi:10.1021/ja211589m · Cited by 128 · see citing works
Self-citationGutbrodt, K. L., Schliemann, C., Giovannoni, L., Frey, K., Pabst, T., Klapper, W., Berdel, W. E., & Neri, D. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006221 · Cited by 108 · see citing works
Self-citationBerndorff, D., Borkowski, S., Sieger, S., Rother, A., Friebe, M., Viti, F., Hilger, C. S., Cyr, J. E., & Dinkelborg, L. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1004-0015 · Cited by 108 · see citing works
Tijink, B. M., Perk, L. R., Budde, M., van Walsum, M., Visser, G. W. M., Kloet, R. W., Dinkelborg, L. M., Leemans, C. R., Neri, D., & van Dongen, G. A. M. S. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1096-y · Cited by 101 · see citing works
Self-citationMaytansine binding to the vinblastine sites of tubulin
Bhattacharyya, B., & Wolff, J. (1977) · FEBS Letters · doi:10.1016/0014-5793(77)80075-6 · Cited by 100 · see citing works
Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT
Tietze, L. F., & Schmuck, K. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798194459 · Cited by 96 · see citing works
Design of Antibody−Maytansinoid Conjugates Allows for Efficient Detoxification via Liver Metabolism
Sun, X., Widdison, W. C., Mayo, M., Wilhelm, S. D., Leece, B. A., Chari, R. V. J., Singh, R., & Erickson, H. K. (2011) · Bioconjugate Chemistry · doi:10.1021/bc100498q · Cited by 92 · see citing works
Demartis, S., Tarli, L., Borsi, L., Zardi, L., & Neri, D. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590100480 · Cited by 90 · see citing works
Self-citationSchliemann, C., Wiedmer, A., Pedretti, M., Szczepanowski, M., Klapper, W., & Neri, D. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.06.025 · Cited by 88 · see citing works
Self-citationStructures of Duocarmycins, novel antitumor antibiotics produced by Streptomyces sp.
Yasuzawa, T., Iida, T., Muroi, K., Ichimura, M., Takahashi, K., & Sano, H. (1988) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.36.3728 · Cited by 87 · see citing works
Hemmerle, T., & Neri, D. (2013) · International Journal of Cancer · doi:10.1002/ijc.28359 · Cited by 84 · see citing works
Self-citationDuocarmycin Analogues Target Aldehyde Dehydrogenase 1 in Lung Cancer Cells
Wirth, T., Schmuck, K., Tietze, L. F., & Sieber, S. A. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201106334 · Cited by 80 · see citing works
Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study
Poli, G. L., Bianchi, C., Virotta, G., Bettini, A., Moretti, R., Trachsel, E., Elia, G., Giovannoni, L., Neri, D., & Bruno, A. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0007 · Cited by 78 · see citing works
Self-citationRadioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies
Erba, P. A., Sollini, M., Orciuolo, E., Traino, C., Petrini, M., Paganelli, G., Bombardieri, E., Grana, C. M., Giovannoni, L., Neri, D., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.101006 · Cited by 77 · see citing works
Self-citationSite-specific chemical modification of antibody fragments using traceless cleavable linkers
Bernardes, G. J. L., Steiner, M., Hartmann, I., Neri, D., & Casi, G. (2013) · Nature Protocols · doi:10.1038/nprot.2013.121 · Cited by 75 · see citing works
Self-citationPalumbo, A., Hauler, F., Dziunycz, P., Schwager, K., Soltermann, A., Pretto, F., Alonso, C., Hofbauer, G. F. L., Boyle, R. W., & Neri, D. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.78 · Cited by 70 · see citing works
Self-citationCloning and characterization of novel tumor-targeting immunocytokines based on murine IL7
Pasche, N., Woytschak, J., Wulhfard, S., Villa, A., Frey, K., & Neri, D. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.04.003 · Cited by 67 · see citing works
Self-citationDuocarmycin Analogues Target Aldehyde Dehydrogenase 1 in Lung Cancer Cells
Wirth, T., Schmuck, K., Tietze, L. F., & Sieber, S. A. (2012) · Angewandte Chemie · doi:10.1002/ange.201106334 · Cited by 67 · see citing works
Antibody–Drug Conjugate Target Selection: Critical Factors
Bander, N. H. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-541-5_2 · Cited by 54 · see citing works
Phase 0 Microdosing PET Study Using the Human Mini Antibody F16SIP in Head and Neck Cancer Patients
Heuveling, D. A., de Bree, R., Vugts, D. J., Huisman, M. C., Giovannoni, L., Hoekstra, O. S., Leemans, C. R., Neri, D., & van Dongen, G. A. M. S. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.111310 · Cited by 49 · see citing works
Self-citationWorld Antibody Drug Conjugate Summit Europe
Beck, A., Senter, P. D., & Chari, R. V. J. (2011) · mAbs · doi:10.4161/mabs.3.4.16612 · Cited by 31 · see citing works
Steiner, M., Hartmann, I., Perrino, E., Casi, G., Samatanga, B., Jelesarov, I., Bernardes, G. J. L., & Neri, D. (2012) · Chemical Science · doi:10.1039/c2sc21107f · Cited by 31 · see citing works
Self-citationTercel, M., McManaway, S. P., Leung, E. Y., Liyanage, H. D. S., Lu, G., & Pruijn, F. B. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201208373 · Cited by 26 · see citing works
Wirth, T., Pestel, G., Ganal, V., Kirmeier, T., Schuberth, I., Rein, T., Tietze, P. L. F., & Sieber, P. S. A. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201208941 · Cited by 26 · see citing works
de Braud, F., Catania, C., Masini, C., Maur, M., Cascinu, S., Berardi, R., Giovannoni, L., Spitaleri, G., Boselli, S., & Neri, D. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e13017 · Cited by 11 · see citing works
Self-citationLajiness, J. P., & Boger, D. L. (2010) · Journal of the American Chemical Society · doi:10.1021/ja106986f · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
WICKI, A. N., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,913 · see citing works
Advances in Chemical Protein Modification
Boutureira, O., & Bernardes, G. J. L. (2015) · Chemical Reviews · doi:10.1021/cr500399p · Cited by 1,137 · see citing works
Self-citationCleavable linkers in antibody–drug conjugates
Bargh, J. D., Isidro‐Llobet, A., Parker, J. S., & Spring, D. R. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00676h · Cited by 658 · see citing works
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 616 · see citing works
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Staudacher, A. H., & Brown, M. P. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.367 · Cited by 550 · see citing works
Antibody-drug conjugates—an emerging class of cancer treatment
Diamantis, N., & Banerji, U. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.435 · Cited by 526 · see citing works
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
Antibody–Drug Conjugates: The Last Decade
Joubert, N., Beck, A., Dumontet, C., & Denevault‐Sabourin, C. (2020) · Pharmaceuticals · doi:10.3390/ph13090245 · Cited by 371 · see citing works
Rossin, R., Versteegen, R. M., Wu, J., Khasanov, A. B., Wessels, H. J. C. T., Steenbergen, E. J., ten Hoeve, W., Janssen, H. M., van Onzen, A. H. A. M., Hudson, P. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03880-y · Cited by 280 · see citing works
Rossin, R., van Duijnhoven, S. M. J., ten Hoeve, W., Janssen, H. M., Kleijn, L. H. J., Hoeben, F. J. M., Versteegen, R. M., & Robillard, M. S. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00231 · Cited by 249 · see citing works
Wichert, M., Krall, N., Decurtins, W., Franzini, R. M., Pretto, F., Schneider, P., Neri, D., & Scheuermann, J. (2015) · Nature Chemistry · doi:10.1038/nchem.2158 · Cited by 217 · see citing works
Self-citationTargeting cancer with antibody-drug conjugates: Promises and challenges
Dean, A. Q., Luo, S., Twomey, J. D., & Zhang, B. (2021) · mAbs · doi:10.1080/19420862.2021.1951427 · Cited by 195 · see citing works
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
Riccardi, F., Bo, M. D., Macor, P., & Toffoli, G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1274088 · Cited by 207 · see citing works
Casi, G., & Neri, D. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00457 · Cited by 193 · see citing works
Self-citationHoffmann, R. M., Coumbe, B. G. T., Josephs, D. H., Mele, S., Ilieva, K. M., Cheung, A., Tutt, A. N. J., Spicer, J. F., Thurston, D. E., Crescioli, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1395127 · Cited by 192 · see citing works
Advances in antibody–drug conjugates: A new era of targeted cancer therapy
Sau, S., Alsaab, H. O., Kashaw, S. K., Tatiparti, K., & Iyer, A. K. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.05.011 · Cited by 177 · see citing works
Mechanisms of action of therapeutic antibodies for cancer
Redman, J. M., Hill, E., Aldeghaither, D. S., & Weiner, L. M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.002 · Cited by 179 · see citing works
Construction of homogeneous antibody–drug conjugates using site-selective protein chemistry
Akkapeddi, P., Azizi, S., Freedy, A. M., Cal, P. M. S. D., Góis, P. M. P., & Bernardes, G. J. L. (2016) · Chemical Science · doi:10.1039/c6sc00170j · Cited by 155 · see citing works
Self-citationCazzamalli, S., Corso, A. D., Widmayer, F., & Neri, D. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b13361 · Cited by 153 · see citing works
Self-citationEvolving Strategies for Target Selection for Antibody-Drug Conjugates
Damelin, M. I., Zhong, W., Myers, J. S., & Sapra, P. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1624-3 · Cited by 153 · see citing works
Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
Kim, E. G., & Kim, K. M. (2015) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2015.116 · Cited by 151 · see citing works
Current methods for the synthesis of homogeneous antibody–drug conjugates
Sochaj, A. M., Świderska, K. W., & Otlewski, J. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.05.001 · Cited by 142 · see citing works
Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates
Pillow, T. H., Sadowsky, J., Zhang, D., Yu, S., Rosario, G. D., Xu, K., He, J., Bhakta, S., Ohri, R. V., Kozak, K. R., et al. (2016) · Chemical Science · doi:10.1039/c6sc01831a · Cited by 142 · see citing works
Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
Singh, A. P., Sharma, S., & Shah, D. K. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9495-8 · Cited by 139 · see citing works
Gébleux, R., Stringhini, M., Casanova, R., Soltermann, A., & Neri, D. (2016) · International Journal of Cancer · doi:10.1002/ijc.30569 · Cited by 124 · see citing works
Self-citationCilliers, C., Guo, H., Liao, J., Christodolu, N., & Thurber, G. M. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9940-z · Cited by 121 · see citing works
Chemotherapeutic drug delivery by tumoral extracellular matrix targeting
Raavé, R., van Kuppevelt, T. H., & Daamen, W. F. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.029 · Cited by 106 · see citing works
Non-internalising antibody–drug conjugates
Ashman, N., Bargh, J. D., & Spring, D. R. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00446a · Cited by 94 · see citing works
Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?
Deonarain, M. P., Yahioglu, G., Stamati, I., Pomowski, A., Clarke, J., Edwards, B. M., Diez-Posada, S., & Stewart, A. (2018) · Antibodies · doi:10.3390/antib7020016 · Cited by 92 · see citing works
Corso, A. D., Cazzamalli, S., Gébleux, R., Mattarella, M., & Neri, D. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00304 · Cited by 92 · see citing works
Self-citationCazzamalli, S., Corso, A. D., & Neri, D. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.023 · Cited by 88 · see citing works
Self-citationMaass, K. F., Kulkarni, C., Betts, A. M., & Wittrup, K. D. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9892-3 · Cited by 85 · see citing works
Joubert, N., Denevault‐Sabourin, C., Bryden, F., & Viaud‐Massuard, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.049 · Cited by 84 · see citing works
Richards, D. A. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.10.005 · Cited by 83 · see citing works
Cazzamalli, S., Ziffels, B., Widmayer, F., Murer, P., Pellegrini, G., Pretto, F., Wulhfard, S., & Neri, D. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3457 · Cited by 82 · see citing works
Self-citationKrall, N., Pretto, F., & Neri, D. (2014) · Chemical Science · doi:10.1039/c4sc00685b · Cited by 78 · see citing works
Self-citationDal Corso, A., Gébleux, R., Murer, P., Soltermann, A., & Neri, D. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.040 · Cited by 75 · see citing works
Self-citationKhera, E., & Thurber, G. M. (2018) · BioDrugs · doi:10.1007/s40259-018-0302-5 · Cited by 72 · see citing works
Patel, T. K., Adhikari, N., Amin, S. A., Biswas, S., Jha, T., & Ghosh, B. (2021) · New Journal of Chemistry · doi:10.1039/d0nj04134c · Cited by 68 · see citing works
Lin, F., Yin, S., Zhang, Z., Yu, Y., Fang, H., Liang, Z., Zhu, R., Zhou, H., Li, J., Cao, K., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.016 · Cited by 68 · see citing works
Emerging formats for next-generation antibody drug conjugates
Deonarain, M. P., Yahioglu, G., Stamati, I., & Marklew, J. S. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1025049 · Cited by 67 · see citing works
Antibody-drug conjugates: Current status and future perspectives
Gébleux, R., & Casi, G. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.07.012 · Cited by 66 · see citing works
Self-citationAntibodies and associates: Partners in targeted drug delivery
Kennedy, P. J., Oliveíra, C., Granja, P. L., & Sarmento, B. F. C. C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.004 · Cited by 69 · see citing works
Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond
Theocharopoulos, C., Lialios, P., Samarkos, M., Gogas, H. J., & Ziogas, D. C. (2021) · Vaccines · doi:10.3390/vaccines9101111 · Cited by 64 · see citing works
Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery
Lingasamy, P., Tobi, A., Haugas, M., Hunt, H., Paiste, P., Asser, T., Rätsep, T., Kotamraju, V. R., Bjerkvig, R., & Teesalu, T. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119373 · Cited by 65 · see citing works
Gébleux, R., Wulhfard, S., Casi, G., & Neri, D. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0480 · Cited by 61 · see citing works
Self-citationWu, M., Huang, W., Yang, N., & Liu, Y. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00347-1 · Cited by 59 · see citing works
Cazzamalli, S., Corso, A. D., & Neri, D. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0283 · Cited by 60 · see citing works
Self-citationSadowsky, J., Pillow, T. H., Chen, J., Fan, F., He, C., Wang, Y., Yan, G., Yao, H., Xu, Z., Martin, S. A., et al. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00258 · Cited by 58 · see citing works
Hooper, A. T., Marquette, K., Chang, C.-P. B., Golas, J., Jain, S., Lam, M., Guffroy, M., Leal, M., Falahatpisheh, H., Mathur, D., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0099 · Cited by 54 · see citing works
Self-citationThe Next Generation of Antibody Drug Conjugates
Mack, F. A., Ritchie, M. F., & Sapra, P. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.08.001 · Cited by 50 · see citing works
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates
Giansanti, F., Capone, E., Ponziani, S., Piccolo, E., Gentile, R., Lamolinara, A., Campli, A. D., Sallese, M., Iacobelli, V., Cimini, A., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.018 · Cited by 46 · see citing works
New Technologies Bloom Together for Bettering Cancer Drug Conjugates
Jin, Y., Zakeri, S. E., Bahal, R., & Wiemer, A. J. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000499 · Cited by 41 · see citing works
Nielsen, C., van Putten, S. M., Lund, I. K., Melander, M. C., Nørregaard, K. S., Jürgensen, H. J., Reckzeh, K., Christensen, K. R., Ingvarsen, S., Gårdsvoll, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17883 · Cited by 40 · see citing works
Prodrugs as drug delivery system in oncology
Delahousse, J., Skarbek, C., & Paci, A. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03906-2 · Cited by 40 · see citing works
Therapeutic antibodies – natural and pathological barriers and strategies to overcome them
Ojaimi, Y. A., Blin, T., Lamamy, J., Gracia, M., Pitiot, A., Denevault‐Sabourin, C., Joubert, N., Pouget, J., Gouilleux‐Gruart, V., Heuzé‐Vourc'h, N., et al. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108022 · Cited by 41 · see citing works
A Chemically Defined Trifunctional Antibody–Cytokine–Drug Conjugate with Potent Antitumor Activity
List, T., Casi, G., & Neri, D. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0599 · Cited by 39 · see citing works
Self-citationDias, A. R. M., Bodero, L., Martins, A., Arosio, D., Gazzola, S., Belvisi, L., Pignataro, L., Steinkühler, C., Corso, A. D., Gennari, C., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900049 · Cited by 37 · see citing works
Noninternalizing Targeted Cytotoxics for Cancer Therapy
Casi, G., & Neri, D. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500798y · Cited by 35 · see citing works
Self-citationGallo, F., Korsak, B., Müller, C., Hechler, T., Yanakieva, D., Avrutina, O., Kolmar, H., & Pahl, A. M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00003 · Cited by 35 · see citing works
Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies
Venetz, D., Hess, C., Lin, C., Aebi, M., & Neri, D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416694112 · Cited by 33 · see citing works
Self-citationCazzamalli, S., Figueras, E., Pethő, L., Borbély, A., Steinkühler, C., Neri, D., & Sewald, N. (2018) · ACS Omega · doi:10.1021/acsomega.8b02350 · Cited by 33 · see citing works
Self-citationDias, A. R. M., Pina, A., Dean, A., Lerchen, H., Caruso, M., Gasparri, F., Fraietta, I., Troiani, S., Arosio, D., Belvisi, L., et al. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201805447 · Cited by 33 · see citing works
Tackling solid tumour therapy with small-format drug conjugates
Deonarain, M. P., & Xue, Q. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa024 · Cited by 33 · see citing works
Targeted Glioma Therapy—Clinical Trials and Future Directions
Shikalov, A. B., Koman, I. E., & Kogan, N. M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16010100 · Cited by 31 · see citing works
Opaliński, Ł., Sokołowska-Wędzina, A., Sochacka, M., Zakrzewska, M., & Otlewski, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-07479-z · Cited by 31 · see citing works
Aubrey, N., Allard-Vannier, É., Martin, C., Bryden, F., Letast, S., Colas, C., Lakhrif, Z., Collinet, N., Dimier‐Poisson, I., Chourpa, I., et al. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00668 · Cited by 31 · see citing works
A “Dual” Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC
Singh, A. P., & Shah, D. K. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.01.034 · Cited by 31 · see citing works
Liang, Y., Li, S., Wang, X., He, B., He, B., Dai, W., Zhang, H., Wang, X., Wang, Y., Zhou, D., et al. (2017) · Theranostics · doi:10.7150/thno.20242 · Cited by 30 · see citing works
Marks, I. S., Gardeen, S. S., Kurdziel, S. J., Nicolaou, S. T., Woods, J. E., Kularatne, S. A., & Low, P. S. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00139 · Cited by 30 · see citing works
Molecular platforms for targeted drug delivery
Maso, K., Grigoletto, A., Vicent, M. J., & Pasut, G. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.03.001 · Cited by 29 · see citing works
Deneka, A. Y., Boumber, Y., Beck, T. N., & Golemis, E. A. (2019) · Cancers · doi:10.3390/cancers11091297 · Cited by 28 · see citing works
The target atlas for antibody-drug conjugates across solid cancers
Fang, J., Guo, L., Zhang, Y., Guo, Q., Wang, M., & Wang, X. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00701-3 · Cited by 26 · see citing works
Douez, E., Allard-Vannier, É., Amar, I. A. M., Jolivet, L., Boursin, F., Maisonial‐Besset, A., Witkowski, T., Chezal, J., Colas, C., Letast, S., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.012 · Cited by 24 · see citing works
Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology
Esnault, C., Schrama, D., Houben, R., Guyétant, S., Desgranges, A., Martin, C., Berthon, P., Viaud‐Massuard, M., Touzé, A., Kervarrec, T., et al. (2022) · Cancers · doi:10.3390/cancers14030778 · Cited by 24 · see citing works
Computational selection of antibody-drug conjugate targets for breast cancer
Fauteux, F., Hill, J. J., Jaramillo, M., Pan, Y., Phan, S., Famili, F. A., & O'Connor‐McCourt, M. D. (2015) · Oncotarget · doi:10.18632/oncotarget.6679 · Cited by 23 · see citing works
Cheung, C. H. P., Chong, T. H., Wei, T., Liu, H., & Li, X. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202217150 · Cited by 20 · see citing works
Miniaturised ‘antibody’-drug conjugates for solid tumours?
Deonarain, M. P. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.09.006 · Cited by 19 · see citing works
APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo
Staudacher, A. H., Li, Y., Liapis, V., Hou, J. J. C., Chin, D. Y., Dolezal, O., Adams, T. E., van Berkel, P. H., & Brown, M. P. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0842 · Cited by 19 · see citing works
Deonarain, M. P., & Yahioglu, G. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1858050 · Cited by 18 · see citing works
β-Glucuronidase triggers extracellular MMAE release from an integrin-targeted conjugate
López, P., Müller, C., Breunig, C., Hechler, T., Pahl, A. M., Arosio, D., Belvisi, L., Pignataro, L., Corso, A. D., & Gennari, C. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob00617f · Cited by 17 · see citing works
Acoustic disruption of tumor endothelium and on-demand drug delivery for cancer chemotherapy
Xu, J., Tu, H., Ao, Z., Chen, Y., Danehy, R., & Guo, F. (2019) · Nanotechnology · doi:10.1088/1361-6528/aafe4e · Cited by 16 · see citing works
Antibody drug conjugates: Development, characterization, and regulatory considerations
Kommineni, N., Pandi, P., Chella, N., Domb, A. J., & Khan, W. (2019) · Polymers for Advanced Technologies · doi:10.1002/pat.4789 · Cited by 16 · see citing works
Ling, Y.-Y., Ren, J. M., Li, T., Zhao, Y., & Wu, C. (2016) · Chemical Communications · doi:10.1039/c6cc00369a · Cited by 16 · see citing works
Zheng, Y., Shen, Y., Meng, X., Wu, Y., Zhao, Y., & Wu, C. (2019) · ChemMedChem · doi:10.1002/cmdc.201900248 · Cited by 16 · see citing works
Kim, S., Kim, H., Jo, D. H., Kim, J. H., Kim, S. R., Kang, D., Hwang, D., & Chung, J. (2018) · Methods · doi:10.1016/j.ymeth.2018.10.002 · Cited by 13 · see citing works
Drug Design of “Undruggable” Targets
Wang, J., Li, S., & Li, H. (2019) · Chinese Journal of Chemistry · doi:10.1002/cjoc.201800552 · Cited by 13 · see citing works
Targeting the Phosphatidylserine-Immune Checkpoint with a Small-Molecule Maytansinoid Conjugate
Lo, C., Chiu, T., Liu, Y., Pan, P.-Y., Liu, K.-L., Hsu, C., Fang, M., Huang, Y., Yeh, T., Hsu, T., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00631 · Cited by 12 · see citing works
Contemporary Approaches to Immunotherapy of Solid Tumors
Kuznetsova, A. V., Glukhova, K. А., Попова, О. П., Петрович, Б. И., & Aa, I. (2024) · Cancers · doi:10.3390/cancers16122270 · Cited by 11 · see citing works
Jolivet, L., Amar, I. A. M., Horiot, C., Boursin, F., Colas, C., Letast, S., Denevault‐Sabourin, C., Allard-Vannier, É., Joubert, N., & Aubrey, N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081524 · Cited by 11 · see citing works
Antibody drug conjugates: the future of chemotherapy?
Borcoman, É., & Tourneau, C. L. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000310 · Cited by 11 · see citing works
Cheung, A., Liu, Y., Chenoweth, A. M., Montaseri, H., Esapa, B., Chudasama, V., Baker, J. R., Thurston, D. E., & Karagiannis, S. N. (2026) · Physiological Reviews · doi:10.1152/physrev.00039.2025 · Cited by 11 · see citing works
Mechanism of Action of AminoCBIs: Highly Reactive but Highly Cytotoxic Analogues of the Duocarmycins
Tercel, M., Pruijn, F. B., O'Connor, P. D., Liyanage, H. D. S., Atwell, G. J., & Alix, S. (2014) · ChemBioChem · doi:10.1002/cbic.201402256 · Cited by 9 · see citing works
Zhang, D., Guo, Y., Zhao, Y., Yu, L., Chang, Z., Pei, H., Huang, J., Chen, C., Xue, H., Xu, X., et al. (2021) · Microbial Cell Factories · doi:10.1186/s12934-021-01559-6 · Cited by 8 · see citing works
Antibody–drug conjugates: targeted weapons against cancer
Scotti, C., Iamele, L., & Vecchia, L. (2015) · Antibody Technology Journal · doi:10.2147/anti.s52914 · Cited by 8 · see citing works
Emerging antibody-based therapies for the treatment of acute myeloid leukemia
Angenendt, L., Mikesch, J., & Schliemann, C. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102409 · Cited by 7 · see citing works
Angenendt, L., Reuter, S., Kentrup, D., Benk, A. S., Neumann, F., Hüve, J., Martens, A. C., Schwöppe, C., Keßler, T., Schmidt, L. H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.208 · Cited by 7 · see citing works
Self-citationAntibody-Drug Conjugates: Targeting the Tumor Microenvironment
Corso, A. D., Cazzamalli, S., & Neri, D. (2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-78154-9_13 · Cited by 7 · see citing works
Self-citationSmall targeted cytotoxics from DNA-encoded chemical libraries
Samain, F., & Casi, G. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.02.009 · Cited by 6 · see citing works
Self-citationAntibody–Drug Conjugates: Empowering Antibodies for the Fight Against Cancer
Denevault‐Sabourin, C., Bryden, F., Viaud‐Massuard, M., & Joubert, N. (2019) · doi:10.1002/9783527814695.ch3 · Cited by 6 · see citing works
- Authors
- Perrino, E., Steiner, M., Krall, N., Bernardes, G. J. L., Pretto, F., Casi, G., & Neri, D.
- Affiliations
- University of Lisbon (PT)
- Venue
- Cancer Research
- Published
- 2014-04-30
- Volume
- 74
- Issue
- 9
- Pages
- 2569-2578
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2073629335
- Cited by
- 130
- References
- 51
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 7 · 2022: 10 · 2021: 9 · 2020: 7 · 2019: 16 · 2018: 17 · 2017: 15 · 2016: 16 · 2015: 17 · 2014: 6
- FWCI
- 14.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Cambridge University Engineering Department Publications Database (submittedVersion)
- Funders
- Novartis Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Kommission für Technologie und Innovation
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- antibody-drug conjugates, maytansinoids, DM1, fibronectin, tumor microenvironment, curative treatment, antigen uptake, extracellular matrix, tumor targeting, CT26 tumor, tissue distribution
- MeSH terms
- Animals, Antibodies, Antineoplastic Agents, Cricetulus, Female, Cricetinae, Humans, Maytansine, Mice, Inbred BALB C, Mice, Nude, Tissue Distribution, CHO Cells, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Embryonal Carcinoma Stem Cells, Mice, 129 Strain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
